Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'
Dermatol Ther (Heidelb)
.
2024 Mar;14(3):819-821.
doi: 10.1007/s13555-024-01106-2.
Epub 2024 Feb 16.
Authors
Mike Bastian
1
,
Nick Freemantle
2
,
Ana B Rossi
3
,
Brad Shumel
4
,
Gaelle Bego Le Bagousse
5
,
Zhixiao Wang
4
,
Yingxin Xu
4
,
Patricia Guyot
5
Affiliations
1
Sanofi, Frankfurt, Germany.
[email protected]
.
2
Institute for Clinical Trials and Methodology, UCL, London, UK.
3
Sanofi, Cambridge, MA, USA.
4
Regeneron Pharmaceuticals Inc., Sleepy Hollow, NY, USA.
5
Sanofi, Gentilly, France.
PMID:
38366176
PMCID:
PMC10965863
DOI:
10.1007/s13555-024-01106-2
No abstract available
Keywords:
Atopic dermatitis; Dupilumab; Eczema; Lebrikizumab; Matching-adjusted indirect comparison.
Publication types
Letter
Comment